This past Christmas weekend, Ana Memedovich had her best two days in more than a decade.
Her 23-year-old son Mikhail has spinal muscular atrophy, or SMA, a rare genetic disease that has slowly robbed him of the ability to walk and... Read more »
You’ve probably seen the Internet memes. “When 2016 started, I looked like this. [Insert picture of young Leo DiCaprio.] Now I look like this. [Leo, with mountain beard, after mud-wrestling with a grizzly in The Revenant.]” In life science terms,... Read more »
We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here, with looks at key studies in... Read more »
[Updated, 4:28 pm ET, see below] After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break... Read more »
’Tis the season for giving gifts. And increasingly, those shiny new toys and gadgets can be connected to the Internet—from TVs to watches, speakers to Barbie dolls.
That Internet connection opens up a ton of possibilities for how we can... Read more »
Slowly but surely, a new group of drugs known as “PARP” inhibitors are starting to become fixtures in the regimens for women with ovarian cancer—and perhaps more. With the approval of a drug called rucaparib (Rubraca) from Clovis Oncology, two have... Read more »
The 21st Century Cures Act is now law. New York wants to play in the biotech big leagues. The FDA under Trump will have license to approve drugs faster and could have a former top official back on board as commissioner.... Read more »
If you’re not much of a podcast listener and you have a sense that you’re missing out on a lot of great content, you’re absolutely right. But now is a good time to fix that, thanks to a new profusion of... Read more »
San Antonio—In a crowd of sport coats, collared shirts, and Oxford shoes, it was easy to spot Brent Barry, and not only because the former NBA player towers above almost everyone. He was also dressed more casually, trading in business... Read more »